trial

Antipsychotic to Treat Psychosis Syndrome

NCTId NCT02137616
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 300 (estimated)
Sponsored by Central South University
Primary completion 2014-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
300 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2012-06
Primary completion
2014-12
Eligibility
ALL · 16 Years · 30 Years

Interventions & indications

Drugs
RisperidoneOlanzapineQuetiapineAripiprazole

Sponsors

Central South UniversityLead Sponsor

Investigators

1
xiaofeng Guo, DrPrincipal Investigator

Sites

1 total
Changsha, China

Facts & assertions

4 sourced
Enrollment
300
Phase
NA
Primary Completion Date
2014-12
Status
UNKNOWN
relationships
The graph out of here
drug
Risperidone
drug
Olanzapine
drug
Quetiapine
drug
Aripiprazole
drug
lead_sponsor
Central South University
company
indication
Psychotic Disorders
indication
Syndrome
indication
Psychotic Disorders
indication
investigator
xiaofeng Guo, Dr
person